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ORIGINAL RESEARCH • BREAST IMAGING
The English National Health Service Breast Screen-ing Program (NHSBSP) began in 1987 following 
the Forrest report (1). Screening for breast cancer aims 
to detect invasive breast cancers at the earliest oppor-
tunity to maximize the success of treatment and thus 
reduce mortality from breast cancer (2). All asymp-
tomatic women registered with a general practitioner 
are invited for screening every 3 years between the ages 
of 50 and 70 years, although since 2010 some women 
from age 45 years and above 70 years have been invited 
as part of the age extensions (or AgeX) trial (3).
Screen-film mammography (SFM) in the NHSBSP 
has been gradually replaced by digital mammography 
(DM), allowing postprocessing and easier acquisition, 
storage, and transfer of images. Image quality especially 
for microcalcification is improved (4). Use of DM be-
gan in 2008 with gradual introduction and by Decem-
ber 31, 2010, over 80% of units had at least one digital 
x-ray set (5). However, it was not until after January 
2011 that DM started to fully replace SFM following 
recommendations in the Department of Health can-
cer strategy report (6). By March 2014, 95% of the 
units were fully digital and all but one unit were partly 
digital (7). The transition from SFM to DM required 
major changes not only in mammography equipment, 
but also investment in supporting computer systems 
for image viewing, communications, archiving, and 
workflow. This may explain the slow rate of transition 
with the NHSBSP.
A number of studies including those of population 
screening programs have compared the effect of DM 
and SFM, suggesting that DM performs at least as well 
as does SFM for cancer detection. However, the direct 
measurement of the effect of DM alone has been lim-
ited by confounding by substantial increases in recall 
rates as a consequence of policy changes, the use of 
computer-aided detection, or switching from single to 
two views simultaneously when changing from SFM to 
DM (4,8,9). In some groups (notably younger women, 
women with dense breasts, and pre- or perimenopausal 
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Purpose: To report the impact of changing from screen-film mammography to digital mammography (DM) in a large organized 
national screening program.
Materials and Methods: A retrospective analysis of prospectively collected annual screening data from 2009–2010 to 2015–2016 for 
the 80 facilities of the English National Health Service Breast Cancer Screening Program, together with estimates of DM usage for 
three time periods, enabled the effect of DM to be measured in a study of 11.3 million screening episodes in women aged 45–70 
years (mean age, 59 years). Regression models were used to estimate percentage and absolute change in detection rates due to DM.
Results: The overall cancer detection rate was 14% greater with DM (P , .001). There were higher rates of detection of grade 1 
and 2 invasive cancers (both ductal and lobular), but no change in the detection of grade 3 invasive cancers. The recall rate was al-
most unchanged by the introduction of DM. At prevalent (first) screening episodes for women aged 45–52 years, DM increased the 
overall detection rate by 19% (P , .001) and for incident screening episodes in women aged 53–70 years by 13% (P , .001).
Conclusion: The overall cancer detection rate was 14% greater with digital mammography with no change in recall rates and with-
out confounding by changes in other factors. There was a substantially higher detection of grade 1 and grade 2 invasive cancers, 
including both ductal and lobular cancers, but no change in the detection of grade 3 invasive cancers.
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Women eligible for breast screening are identified from 
the National Health Service database and invited every 3 
years by one of the 80 breast screening facilities in England. 
Bilateral two-view mammography, predominantly performed 
in mobile vans, is independently double read by film read-
ers with defined national standards for training, caseloads 
and service, and performance. Film readers include accred-
ited breast subspecialist radiologists and advanced practice 
mammographers. Arbitration (usually performed by a radi-
ologist or panel of film readers) is undertaken for mammo-
grams where there is a discrepancy between readers' opinions. 
Women recalled for further investigation (assessment) attend 
the responsible screening service. Assessment is conducted 
according to national guidance and all women undergoing 
biopsy are discussed at multidisciplinary team meetings (12).
Data Collection
Annual categorical data returns are produced for each of the 
80 screening facilities where women with screening episodes 
opened during April 1 to March 31 are followed up to mea-
sure recall, biopsy rates, and cancer detection for each screen-
ing type (eg, first invitation, routine invitation to previous 
nonattender, or routine invitation to previous attender) by 
using 10 age bands. All facilities report the same information 
with uniform definitions ensuring comparability. The full 
data set consisted of 12.5 million routine screening episodes, 
and the analysis data set restricted the data to prevalent (first 
invitation) screening episodes at ages 45–52 years (age bands, 
45–49 years and 50–52 years) and incident (subsequent) 
screening episodes at ages 53–70 years (age bands, 53–54 
years, 55–59 years, 60–64 years, 65–69 years, and 70 years) 
to ensure maximum comparability across years.
Additional annex data sets give details on all individual 
cancers (grade, size, and nodal status) detected within each 
screening type and age band and have been linked to the 
main returns to produce the analysis data set. Grade is given 
as 1, 2, or 3 for invasive cancers and as high or low to inter-
mediate for ductal carcinoma in situ (DCIS). For prevalent 
screening episodes, the denominator is women but for inci-
dent screening episodes, the denominator is woman-episode 
because some women will have had two episodes over the 
study period.
Each facility has a static (hospital-based) mammography 
unit and several mobile vans or satellite facilities each with a 
mammography unit. These mammography units were grad-
ually replaced by digital systems over the period from 2008 
to 2015. Records of the change from SFM to DM for each 
of the 80 facilities and associated mammography units were 
kept by the national screening office at four different time 
periods over the conversion period. These records have been 
used to estimate the percentage of screening episodes un-
dertaken with DM and SFM screening over the conversion 
period, and the estimate of percentage of digital usage at any 
time during the conversion process has been obtained by 
using a Gompertz model (Figure E1 [online]). Data analysis 
was conducted by R.G.B. (epidemiologist with 35 years of 
relevant experience).
Abbreviations
CI = confidence interval, DCIS = ductal carcinoma in situ, DM = digital 
mammography, NHSBSP = National Health Service Breast Screening 
Program, SFM = screen-film mammography
Summary
The overall cancer detection rate was 14% greater with digital mam-
mography compared with screen-film mammography, with substan-
tially higher detection of grade 1 and grade 2 invasive cancers but no 
change in the detection of grade 3 invasive cancers.
Implications for Patient Care
 n Detection of some potentially life-threatening cancers is higher 
with digital mammography (DM) than screening mammography.
 n DM has greater sensitivity at the same recall rate as screen-film 
mammography.
 n DM results in improved effectiveness for breast cancer screening 
compared with screening mammography.
women), the sensitivity of DM has been estimated to be 
higher than that of SFM (10,11). There is a lack of evidence 
in large populations on the direct effect of DM at a similar 
recall rate to SFM imaging.
This study examines the impact of DM on cancer detec-
tion rates and recall rates and aims to estimate the effect of 
DM in increasing detection rates for both prevalent (first) 
and incident (subsequent) screening episodes from women 
invited every 3 years.
Materials and Methods
The NHSBSP has gained approval to access and process pa-
tient data for the purposes of quality assuring the NHSBSP 
under section 251 of the Health and Social Care Act 2008 
through approval of the Confidentiality Advisory Group 
(previously the National Information Governance Board for 
Health and Social Care). Because this study did not involve 
patient contact, intervention, or use of identifiable patient 
data, it was determined to be exempt from human subject 
ethical review in the United Kingdom. Ethics committee 
approval was therefore not required and written informed 
consent was waived.
No industry support was provided for this study. The 
authors had control of the information submitted for 
publication.
Study Population
This study was undertaken by using data from an ongoing 
population-based breast screening program for asymptom-
atic women aged 50–70 years. The NHSBSP uses a single 
national information technology system, the National 
Breast Screening Computer System, and collects standard-
ized data on all breast screening activity by each facility. 
This information is published annually by National Health 
Service Digital and is anonymized. The study is divided into 
three time periods (early, middle, and late digital implemen-
tation periods) with different penetrance of digital usage. 
The age range of women screened is 45–70 years, with a 
mean age of 59 years.
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Table 1: All Screening Episodes Ages 45–70 Years Observed Rates by Implementation Period Showing Observed Can-
cer Detection Rates, Percentage Change from Early to Late Implementation Period, and Estimated Full Effect of DM
Implementation Period
Variable
Early  
(2009–2011)
Middle  
(2011–2014)
Late  
(2014–2016)
Change in
Detection Rate, 
Late vs Early 
Period (%)*
Estimated 
Detection  
Rate† Increase (%)‡
Absolute Increase 
from Digital‡
Estimated digital 
usage (%)
34.6 81.0 98.0 … … … …
Mean recall rate (%) 3.81 3.98 3.88 … … … …
Screening episodes 3 100 963 4 918 765 3 238 892 … … … …
Mean age (y) 59.4 59.1 59.4 … … … …
All cancers 22 626 (7.30) 38 120 (7.75) 25 697 (7.93) 9 (,.001) 6.95/7.95 14 (11, 17) 
[,.001]
1.00 (0.79, 1.20) 
[,.001]
Unknown or  
 missing status
29 42 21 … … … …
Invasive 17 953 (5.79) 29 729 (6.04) 19 999 (6.17) 7 (,.001) 5.59/6.17 10 (7, 14) 
[,.001]
0.59 (0.41, 0.77) 
[,.001]
Grade 3 3713 (1.20) 6086 (1.24) 3894 (1.20) 0 (.81) 1.20/1.22 2 (25, 9)  
[.53]
0.03 (20.06, 0.11) 
[.53]
Grade 1 and 2 14 026 (4.52) 23 350 (4.75) 15 965 (4.93) 9 (,.001) 4.30/4.90 14 (10, 18) 
[,.001]
0.60 (0.44, 0.76) 
[,.001]
Unknown  
 invasive grade
214 293 140 … … … …
Microinvasive 224 (0.07) 302 (0.06) 188 (0.06) 212 (.22) 0.10/0.08 229 (247, 6) 
[.02]
20.02 (20.04, 0.00) 
[.02]
Noninvasive 4420 (1.43) 8047 (1.64) 5489 (1.69) 19 (,.001) 1.28/1.71 32 (24, 40) 
[,.001]
0.43 (0.34, 0.53) 
[,.001]
High-grade DCIS 2509 (0.81) 4587 (0.93) 3238 (1.00) 24 (,.001) 0.71/1.00 39 (28, 50) 
[,.001]
0.29 (0.22, 0.36) 
[,.001]
Low- to intermediate- 
 grade DCIS
1676 (0.54) 3021 (0.61) 1994 (0.62) 14 (,.001) 0.50/0.63 25 (13, 38) 
[,.001]
0.13 (0.07, 0.19) 
[,.001]
Unknown invasive  
 grade
235 439 257 … … … …
IHG 20 686 (6.67) 34 618 (7.04) 23 425 (7.23) 8 (,.001) 6.36/7.22 13 (10, 17) 
[,.001]
0.86 (0.67,1.05) 
[,.001]
Note.—Unless otherwise specified, data in parentheses are the rate per 1000 women screened. DCIS = ductal carcinoma in situ, DM = 
digital mammography, IHG = invasive, microinvasive, high-grade DCIS.
* Data in parentheses are P values.
† Data indicates estimated rate at 100% film usage and 100% digital usage.
‡ Data in parentheses are 95% confidence intervals, with P values in brackets.
Analysis and Modeling
Screening with DM was first introduced in 2008 but not 
fully implemented until 2015. The seven screening years from 
2009–2010 to 2015–2016 have been divided into three groups 
(early, middle, and late digital conversion periods). Mean age 
for each period is calculated by using a weighted mean age, 
where the midpoint age is multiplied by the number of screen-
ing episodes in that age band and divided by the total screening 
episodes from all the age bands.
In the first 2 years (2009–2010 and 2010–2011, or the early 
period), we estimated DM usage of 34.6%. We considered the 
years 2011–2012, 2012–2013, and 2013–2014 to be the transi-
tion years (or middle period) with estimated DM usage of 81%, 
and for the final 2 years (2014–2015 and 2015–2016, or late 
period) we estimated DM usage of 98%. Further details are 
given in Appendix E1 (online).
Statistical Analysis
The percentage change in cancer detection rate between the 
early and late implementation period was calculated, and the 
significance was calculated from a test of two proportions. As-
suming negligible change in background incidence (see the 
Results section), this will underestimate the full effect of DM 
as the early implementation period had DM usage of 34.6%. 
To estimate the full effect and use all the data including the 
middle implementation period, a binomial regression model 
was used to determine the risk ratio and risk difference be-
tween 0% and 100% digital use by producing models with 
Impact of Digital Mammography on Cancer Detection and Recall Rates
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Table 2: All Screening Episodes Ages 45–70 Years Observed Rates by Implementation Period with Detailed Histologic 
Type for Invasive Cancers Showing Observed Cancer Detection Rates, Percentage Change from Early to Late Imple-
mentation Period, and Estimated Full Effect of DM
Implementation Period
Variable
Early 
(2009–2011)
Middle 
(2011–2014)
Late 
(2014–2016)
Change in Detec-
tion Rate, Late vs 
Early Period (%)*
Estimated 
Detection  
Rate† Increase (%)‡
Absolute Increase 
from Digital‡
Invasive 17 953 (5.79) 29 729 (6.04) 19 999 (6.17) 10 (,.001) 5.58/6.17 10 (7, 14) 
[,.001]
0.59 (0.41, 0.77) 
[,.001]
DN 13 139 (4.24) 21 623 (4.40) 14 312 (4.42) 4 (,.001) 4.14/4.44 7 (3, 11)  
[,.001]
0.30 (0.15, 0.46) 
[,.001]
DN grade 1 3204 (1.03) 5378 (1.09) 3657 (1.13) 9 (,.001) 0.98/1.13 15 (7, 23) 
[,.001]
0.15 (0.07, 0.22) 
[,.001]
DN grade 2 6606 (2.13) 10 950 (2.23) 7356 (2.27) 7 (,.001) 2.05/2.27 10 (5, 16) 
[,.001]
0.22 (0.11, 0.33) 
[,.001]
DN grade 3 3300 (1.06) 5249 (1.07) 3258 (1.01) 25 (.02) 1.10/1.03 26 (213, 1) 
[.09]
20.07 (20.14, 0.00) 
[.09]
LP 1854 (0.60) 3101 (0.63) 2183 (0.67) 13 (,.001) 0.56/0.66 19 (8, 31) 
[,.001]
0.11 (0.05, 0.16) 
[,.001]
MP 236 (0.08) 441 (0.09) 301 (0.09) 10 (.02) 0.07/0.09 38 (6, 79) [.015] 0.03 (0.01, 0.05) 
[.012]
TP + TM 765 (0.25) 1182 (0.24) 750 (0.23) 26 (.22) 0.26/0.23 28 (221, 7) 
[.25]
20.02 (20.06, 0.02) 
[.25]
MD + OP + 
OX
1161 (0.37) 1830 (0.37) 1209 (0.37) 0 (.94) 0.38/0.37 21 (212, 12) 
[.91]
20.02 (20.05, 0.04) 
[.91]
Not known 798 (0.26) 1552 (0.32) 1244 (0.38) … … … …
Mean size 
(mm)
16.28 16.20 16.16 … 16.53/16.16 20.37 (.046)* …
Node positive 
(%)
21.2 21.0 20.1 … 21.8/20.5 21.2 (.053)* …
Note.— Unless otherwise specified, data in parentheses are the rate per 1000 women screened. Histologic types for invasive cancers are duc-
tal (DN); lobular (LP); mixed (MP); tubular and tubular mixed (TP + TM); and medullary, other primary cancer, and other mixed (MD + 
OP + OM). DCIS = ductal carcinoma in situ, DM = digital mammography.
* Data in parentheses are P values.
† Data indicates estimated rate at 100% film usage and 100% digital usage.
‡ Data in parentheses are 95% confidence intervals, with P values in brackets.
proportion of digital usage (0.346, 0.810, and 0.980) against 
proportion of screened women with cancer detected in each 
of the three groups. Prevalent screening episodes (ages 45–52 
years) and incident screening episodes (ages 53–70 years) were 
analyzed separately and combined. For the combined data, the 
mean age was almost the same across the implementation pe-
riod. For prevalent screening episodes, there was a small dif-
ference (a trend) in mean age between the three groups (up 
to 10 months), and we adjusted the rate to the midpoint of 
50.2 years. For incident screening episodes, the difference was 
3 months (again with a trend), and we adjusted the rates to 
the midpoint age of 61.6 years. Adjustments used regression 
models of cancer detection rate with age. All statistical analy-
ses used Stata (versions 14 or 15; StataCorp, College Station, 
Tex). A P value of , .05 was considered to indicate statistical 
significance.
Histologic type for invasive cancers has been grouped 
into five main groups: (a) ductal, (b) lobular, (c) mixed, 
(d) tubular and tubular mixed and medullary, and (e) other 
primary cancer and other mixed. Because of the large num-
ber of ductal invasive cancers, these have also been analyzed 
as grade 1, grade 2, and grade 3 cancers. Nearly all lobular 
invasive cancers are given as grade 2. There are insufficient 
numbers of the other cancers to divide further. DCIS is 
recorded as high nuclear grade and intermediate and low 
nuclear grade combined and also associated microinvasive 
cancer (foci of invasion, ,1 mm in diameter).
Results
In the analysis data set, there were 11 258 620 routine 
screening episodes, of which 2 295 016 were routine prev-
alent (first) screening episodes at age 45–52 years and 
8 963 604 incident (subsequent) screening episodes at age 
53–70 years. From these screening tests, there were 86 443 
(7.7 per 1000 women screened) cancers.
Table 1 shows the observed rates of recall and can-
cer detection for all screening episodes over the three 
time periods for invasive, microinvasive, and noninvasive 
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cancers. Recall rates are stable. For all 
cancers there was a 9% (P , .001) 
change in detection rates between the 
early (7.30 per 1000) and late (7.93 per 
1000) implementation periods (22 626 
of 3 100 963 vs 25 697 of 3 238 892). 
By using binomial regression, the esti-
mated SFM cancer detection rate was 
6.95 per 1000, which increased by 1.00 
per 1000 to 7.95 per 1000 for fully digi-
tal screening (P , .001), an estimated 
increase of 14% (P , .001). The largest 
increase was for grade 1 and 2 invasive 
cancers (0.60 per 1000) followed by high-
grade DCIS (0.29 per 1000) and low- 
to intermediate grade DCIS (0.13 per 
1000). There was no increase in grade 3 
invasive cancers. There were 13 675 grade 
3 invasive cancers in the study, and the 
difference between film and digital was 
0.03 (95% confidence interval [CI]: 0.06, 
0.11) per 1000 (P = .53 showing little or 
no effect in the detection of these cancers).
Table 2 shows the results for invasive 
cancers by detailed histologic type, show-
ing higher detection of invasive cancers, 
mostly grade 1 and 2 invasive ductal can-
cers and lobular cancers. The estimated 
mean invasive cancer size was reduced from 
16.53 mm for film to 16.16 mm for digi-
tal, a difference of 20.37 mm (P = .046).
Further details of ductal invasive and 
lobular invasive cancers by size for all epi-
sodes are shown in Table 3. The models 
estimate that DM had higher detection 
of ductal invasive grade 2 cancer for both 
small tumors (,15 mm) by 0.14 per 1000 
(P = .001) and larger tumors (15 mm) 
by 0.08 per 1000 (P = .03). In contrast, 
DM only increased the detection of small 
(,15 mm) grade 1 invasive ductal can-
cers (0.15 per 1000), with no increase in 
larger (15 mm) grade 1 ductal cancers. 
Overall, there was no change in grade 3 
ductal invasive cancers and no change in 
the overall detection of 15-mm invasive 
ductal cancers over the implementation 
period (P = .88). If we assume the larger 
ductal cancers are detected by film or digi-
tal, then we can infer there was little or no 
change in background incidence over the 
period. For lobular invasive cancers (Table 
3) there was also evidence that both small 
(,15 mm) and larger (15 mm) cancer 
detection rates increased by 0.05 per 1000 
(P = .003) and 0.05 per 1000 (P = .03), 
respectively.
Table 3: All Screening Episodes Ages 45–70 Years Observed Rates by 
Implementation Period for Ductal Invasive Cancers by Size with Per-
centage Small (<15 mm) or Large (≥15mm) Change over Implementa-
tion Period and Estimated Increase from DM
Observed Rate by Size
Variable <15 mm ≥15 mm
Ductal invasive cancer, grade 1
 Implementation period
  Early 2288 (71) [0.74] 913 (29) [0.29]
  Middle 3932 (73) [0.80] 1444 (27) [0.29]
  Late 2726 (75) [0.84] 929 (25) [0.29]
 Change in rate, late vs early* 0.10 (<.001) 0.00 (.58)
 Estimated increase from  
   DM*
0.15 (<.001) 0.00 (.65)
Ductal invasive cancer, grade 2
 Implementation period
  Early 3640 (55) [1.17] 2958 (45) [0.95]
  Middle 6053 (55) [1.23] 4889 (45) [0.99]
  Late 4100 (56) [1.27] 3256 (44) [1.01]
 Change in rate, late vs early* 0.09 (<.001) 0.05 (.04)
 Estimated increase from  
   DM*
0.14 (.001) 0.08 (.03)
Ductal invasive cancer, grade 3
 Implementation period
  Early 1323 (40) [0.43] 1972 (60) [0.64]
  Middle 2072 (40) [0.42] 3171 (60) [0.64]
  Late 1320 (41) [0.41] 1937 (59) [0.60]
 Change in rate, late vs early* −0.02 (.24) −0.0.04 (.06)
 Estimated increase from  
   DM*
0.00 (.30) 0.00 (.19)
Lobular invasive cancers
 Implementation period
  Early† 650 (35) [0.21] 1201 (65) [0.39]
  Middle‡ 1119 (36) [0.23] 1978 (64) [0.40]
  Late§ 801 (37) [0.25] 1379 (63) [0.43]
 Change in rate, late vs early* 0.04 (.002) 0.04 (.02)
 Estimated increase from  
   DM*
0.05 (.003) 0.05 (.03)
Note.—Unless otherwise specified, data in parentheses are percentages and data in 
brackets are the rate per 1000 women screened. Overall rate for all grades of <15 mm 
increased from 2.34 per 1000 to 2.52 per 1000 (test of trend P < .001) over the early 
to late periods, but for all grades ≥15 mm the rate increased from 1.88 to 1.89 (test 
of trend P = .88). There is, therefore, no change in the larger ductal invasive cancers 
over the early to late periods suggesting no major change in background incidence, 
and the effect of digital is mostly in the detection of small invasive ductal cancers. 
DM = digital mammography.
* Data in parentheses are P values.
† 3 100 963 screening episodes.
‡ 4 918 765 screening episodes.
§ 3 238 892 screening episodes.
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an absolute increase of 0.91 per 1000 (Table 4A). There 
were increases for grade 1 and 2 invasive cancers (13%; P 
, .001), high-grade DCIS (31%; P , .001), and low- to 
intermediate-grade DCIS (22%; P = .001). The exception 
was for grade 3 invasive cancers,  where there was no change 
in the cancer detection rate of DM compared with SFM 
(21%; P = .85). Table 4B shows the results by histologic 
type and grade of invasive cancer. Grade 1 and 2 ductal 
cancers (16% [P , .001] and 9% [P = .002], respectively) 
and lobular invasive cancers (18% [P , .001]) all showed 
Table 4 shows the estimated detection rates for film and digi-
tal and the increase in detection rates at prevalent and incident 
screening episodes. At prevalent screening episodes (ages 45–52 
years), there was an increase in all cancers of 19% from 6.33 to 
7.59 per 1000, which was a difference of 1.26 per 1000 (P , 
.001). Invasive cancers increased by 12% (0.57 per 1000 from 
4.72 to 5.29 per 1000 [P = .004]) and high-grade DCIS by 64% 
(0.52 per 1000 from 0.71 to 1.23 per 1000 [P , .001]).
The incident screening episode cancer detection rates in-
creased by 13% from 7.11 to 8.02 per 1000 (P , .001), 
Table 4: Estimated Effect of DM for Prevalent (First) and Incident (Subsequent Screening Episodes) by Grade of Cancer 
and Histologic Type
A: Grade of Cancer
Prevalent Screening Episode (45–52 y)* Incident Screening Episode (53–70 y)†
Variable
Estimated  
Rate, 100%  
Film
Estimated  
Rate, 100%  
Digital Increase (%)‡
Absolute  
Increase‡
Estimated  
Rate, 100%  
Film
Estimated  
Rate, 100%  
Digital Increase (%)‡
Absolute  
Increase‡
All cancers 6.33 7.59 19 (,.001) 1.26 (,.001) 7.11 8.02 13 (,.001) 0.91 (,.001)
Invasive 4.72 5.29 12 (.005) 0.57 (.004) 5.81 6.39 10 (,.001) 0.59 (,.001)
Grade 3 0.84 0.99 17 (.08) 0.15 (.07) 1.31 1.30 21 (.85) 20.01 (.84)
Grade 1 and 2 3.88 4.30 11 (.019) 0.42 (.017) 4.50 5.09 13 (, .001) 0.59 (.001)
Microinvasive 0.08 20.06 224 (.40) 0.02 (.42) 0.08 0.06 231 (.02) 20.02 (.03)
Noninvasive 1.52 2.24 43 (,.001) 0.72 (,.001 1.22 1.57 27 (,.001) 0.35 (,.001)
High-grade DCIS 0.71 1.23 64 (,.001) 0.52 (,.001) 0.76 1.00 31 (, .001) 0.24 (,.001)
Low- to intermediate- 
 grade DCIS 
0.82 1.02 23 (.02) 0.20 (.02) 0.47 0.57 22 (.001) 0.10 (.001)
IHG 5.52 6.58 19 (,.001) 1.06 (,.001) 6.64 7.44 12 (,.001) 0.80 (,.001)
B: Histologic Type
Prevalent Screening Episode (45–52 y)§ Incident Screening Episode (53–70 y)║
Variable
Estimated  
Rate, 100%  
Film
Estimated  
Rate, 100%  
Digital Increase (%)‡
Absolute  
Increase‡
Estimated  
Rate, 100%  
Film
Estimated  
Rate, 100%  
Digital Increase (%)‡
Absolute  
Increase‡
Invasive 4.72 5.29 12 (.004) 0.57 (.004) 5.81 6.39 10 (,.001) 0.59 (,.001)
DN 3.43 3.77 10 (.04) 0.34 (.04) 4.32 4.60 6 (.002) 0.28 (.002)
DN grade 1 0.97 1.03 7 (.44) 0.07 (.44) 0.99 1.15 16 (,.001) 0.16 (,.001)
DN grade 2 1.71 1.92 12 (.07) 0.22 (.06) 2.15 2.34 9 (.002) 0.20 (.002)
DN grade 3 0.76 0.80 6 (.55) 0.05 (.53) 1.18 1.09 28 (.03) -0.10 (.03)
LP 0.43 0.51 19 (.17) 0.09 (.15) 0.59 0.70 18 (.001) 0.11 (.001)
MP 0.04 0.04 8 (.85) 0.00 (.85) 0.07 0.11 43 (.01) 0.03 (.01)
TP + TM 0.33 0.27 220 (.17) 20.06 (.18) 0.24 0.22 25 (.53) 20.01 (.53)
MD + OP + OX 0.34 0.32 28 (.57) 20.03 (.56) 0.38 0.39 1 (.92) 0.00 (.92)
Note.—Unless otherwise specified, data are the rate per 1000 women screened. Histologic type for invasive cancers are ductal (DN); lobular 
(LP); mixed (MP); tubular and tubular mixed (TP + TM) and medullary; other primary cancer and other mixed (MD + OP + OM). DCIS 
= ductal carcinoma in situ, DM = digital mammography, IHG = invasive, microinvasive, high-grade DCIS.
* Mean age for early, middle, and late periods was 50.8 years, 50.2 years, and 50.0, years, respectively. By using prevalent screening episode 
data for all years, the association between age and cancer detection rate at these ages ranges was estimated and corrected to the middle 
period age of 50.2 years (early rates multiplied by 0.966 and digital by 1.011).
† Mean age for early, middle, and late periods was 61.4 years, 61.6 years, and 61.7 years, respectively. By using the modeled association 
between age and cancer detection rate, mean age was adjusted to 61.6 years (early rates multiplied by 1.0095 and late by 0.995). These cor-
rection factors were applied to all types of cancer (all rows).
‡ Data in parentheses are P values.
§ All three groups adjusted to age 50.2 years.
║ Adjusted to age 61.6 years as per Table 4A. 
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highly significant greater detection rates from DM for inci-
dent screening episodes. In contrast, grade 3 ductal invasive 
cancers showed a reduction of 8% (P = .03).
Discussion
In this very large study of the NHSBSP, we found that DM was 
associated with significantly greater cancer detection rates with-
out changing recall rates. Our main findings are that the overall 
cancer detection rate was 14% greater with DM, with substan-
tially higher detection of grade 1 and grade 2 invasive cancers, 
including both ductal and lobular cancers, but no change in the 
detection of grade 3 invasive cancers.
Many previous studies of the introduction of DM have been 
associated with higher rates of recall for assessment in both 
American and European programs (9,13,14). A large study from 
Holland (15) of 6 million screening episodes showed higher de-
tection rates of DCIS. However, in that period there was a delib-
erate policy to increase recall rates, which almost doubled in the 
incident screening episode from 2.3% to 4.4% (8,16). Previous 
studies have struggled to separate the absolute effect of DM from 
the higher detection rates that would occur from use of SFM by 
merely increasing recall rates (Table 5). We adjusted for small 
variations in mean age between the study periods where required 
and inferred negligible change in background incidence over the 
study period. With no change in recall rates, we therefore con-
clude that our study reports the unbiased impact on detection 
rates of changing from SFM to DM.
Higher Cancer Detection Is Seen in Both Older and 
Younger Women
Early studies of the introduction of DM indicated that the prin-
ciple gain in cancer detection occurred in younger women and 
those with dense breasts. In the Digital Mammography Screening 
Trial (or DMIST) study, women younger than 50 years at screen-
ing showed an increase of 0.15 in area under receiver operating 
Table 5: Comparison of Study with Previous Screening Observational Studies
Year Author
Age  
Range (y)
No. of 
Screening 
Episodes 
Studied
Screening 
Frequency 
(y)
Recall Rate at 
First Screening 
(%)*
Recall Rate at 
Subsequent 
Screening  
Episodes (%)*
Cancer  
Detection  
Rate at First 
Screening
Episode (%)*
Cancer  
Detection Rate 
at Subsequent 
Screening  
Episodes (%)* Confounders
2018 Blanks et al 45–70 11.3 million 3 7.7/7.7  
(.93)
2.9/2.9  
(.99)
0.633/0.759 
(,.001)
0.711/0.802 
(,.001)
…
2007 Del Turco  
 et al (4)
50–69 28 770 2 7.8/7.53  
(.77)
3.44/4.15 
(,.003)
0.82/0.74  
(0.79)
0.55/0.72 
(0.09)
Recall rate  
 increased
2013 Van Luijt  
 et al (15)
50–75 6.0 million 2 3.2/4.6 
(,.001)
1.7/1.6  
(,.001)
0.56/0.7 
(,.001)
0.46/0.53 
(,.001)
Recall rate  
 increased,  
 introduction 
 of CAD
2014 Seradour  
 et al (9)
50–74 162 257 2 6.11/7.78 
(,.001)†
… 0.66/0.71† … Recall rate  
 increased
Note.—CAD = computer-aided detection.
* Indicates screen-film mammography versus digital mammography. Data are the rate per 1000 women screened,  
with P values in parentheses.
† Indicates all screenings.
characteristic curve, with only an increase of 0.03 in women of all 
ages (4,10).
At prevalent screening episodes (ages 45–52 years), the 
impact of DM is highest for the detection of high-grade 
DCIS with a substantial increase of around 64% (0.52 per 
1000; P , .001)). There was a smaller increase in low- to 
intermediate-grade DCIS of 0.20 per 1000 (P = .016). This 
supports previous findings of a large increase in the detection 
of DCIS at initial screening examinations with DM probably 
related to improved visualization of microcalcifications (4,8). 
Calcification representing DCIS is well seen at DM (Fig 1). 
In agreement with previous studies, we also showed superior-
ity of DM over SFM for demonstration of invasive cancers, 
which are more likely to manifest as soft-tissue lesions radio-
logically (17,18).
There was no evidence of an increase in grade 3 invasive can-
cers (Fig 2). The absolute increase at both prevalent and incident 
screening episodes combined was 0.03 (95% CI: 0.06, 0.11) per 
1000 (P = .53), thereby ruling out any large increase in the detec-
tion of these cancers. This is counter to previous findings of an 
increase in grade 3 invasive ductal carcinoma in the French screen-
ing program with DM (9).
That recall rates were largely unchanged in our study may be 
because there are carefully monitored target rates within the pro-
gram and screening facilities tend to maintain stable rates over 
time. Facilities are also are reluctant to reduce recall rates in case 
cancers are missed.
Interval Cancers and Mortality
Interval cancer data from this period were incomplete and 
therefore not included in our study. Previous studies have 
shown conflicting impact of DM on interval cancer rates 
with some evidence of a reduction in interval cancer rates 
associated with increased sensitivity of DM (11) and other 
studies showing no difference in rates (19).
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Technical Considerations 
around Conversion to Digital
Digital screening in England during 
the early years of the period studied 
included a small amount of com-
puted radiography. This was inferior 
to DM in cancer detection (9). From 
2010, no new computed radiogra-
phy units were installed and those 
in use were phased out; the number 
of units was too small to impact our 
results. During the introduction of 
DM, a number of units would print 
out the digital image and read the 
hard copy (20), reducing the po-
tential gains in efficiency and image 
quality, but allowing a mixed econ-
omy of DM and SFM to be man-
aged during a transition period. The 
quality of such hard-copy images was not 
inferior to SFM (20).
Limitations of the Study
The NHSBSP data set uses aggregated 
data and does not provide information on 
factors such as breast density, tumor recep-
tors, or radiologic features prompting re-
call. Other limitations were the estimated 
use of DM with time and the assumption 
of no confounding by background inci-
dence. These weaknesses are counterbal-
aced by the size of the overall data set and 
uniformity of screening practice and data 
collection. The introduction of DM units 
at screening facilities as older mammog-
raphy units were replaced means that the 
study is unlikely to be biased by popula-
tion characteristics.
In conclusion, we have shown that 
the overall cancer detection rate was 14% 
greater with digital mammography but 
had no effect on the detection of grade 
3 invasive cancers. Future studies should 
seek to determine how digital mammogra-
phy could be improved to increase detec-
tion of grade 3 invasive cancers.
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